These unprecedented times may have provided unprecedented adversity, but there is still so much for which to be thankful. Let’s review.

The story of how Paula Ragan, Ph.D., went from aspiring academic to biopharmaceutical protégé to CEO of X4 Pharmaceuticals, a six-year-old company focused on improving the immune system for treating rare diseases.

A call with a young reader reveals a biopharmaceutical industry mentorship opportunity beyond science.

For years we’ve been hearing that “print” is dead. Despite the statistics, I still don’t believe this pandemic — or anything else — is going to eradicate publications printed on paper.

Biopharma CEO wasn’t David Lucchino’s first, second, or even third choice as a career path. Today, though, he uses elements of his diverse background to lead his second pharma startup, Frequency Therapeutics.

With the annual J.P. Morgan Healthcare conference going virtual in January of 2021, Rob Wright asks readers about their business travel plans for next year, and includes anonymized thoughts on posed questions from two Life Science Leader editorial advisory board members.

Tim Wright shares his due diligence approach regarding MiMedx before becoming its CEO in 2019, along with how he went about implementing his 90-day business plan that would transform the company.

How many CEOs of publicly traded companies do you think can claim to driving the exact same car that they did when they first got their start? Tim Wright can.

CEO Andrea Pfeifer talks about why, years ago, she was convinced it was time to leave her career in the food industry and cofound AC Immune, a biopharma focused on one of the most difficult areas — Alzheimer’s disease.